pABri treated mice did not differ significantly by posthoc testing from wild-type controls, although there was a clear trend for wild-type mice to have less CD11b immunoreactivity.
← all excerpts
Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease.
1
—
—